East Tennessee State University

Digital Commons @ East Tennessee State University
ETSU Faculty Works

Faculty Works

7-1-2020

Microgravity, Bone Homeostasis, and Insulin-Like Growth Factor-1
John Kelly Smith
Quillen-Dishner College of Medicine, smithj@etsu.edu

Follow this and additional works at: https://dc.etsu.edu/etsu-works

Citation Information
Smith, John Kelly. 2020. Microgravity, Bone Homeostasis, and Insulin-Like Growth Factor-1. Applied
Sciences (Switzerland). Vol.10(13). https://doi.org/10.3390/app10134433

This Review is brought to you for free and open access by the Faculty Works at Digital Commons @ East
Tennessee State University. It has been accepted for inclusion in ETSU Faculty Works by an authorized
administrator of Digital Commons @ East Tennessee State University. For more information, please contact
digilib@etsu.edu.

Microgravity, Bone Homeostasis, and Insulin-Like Growth Factor-1
Copyright Statement
© 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed
under the terms and conditions of the Creative Commons Attribution (CC BY) license
(http://creativecommons.org/licenses/by/4.0/).

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This review is available at Digital Commons @ East Tennessee State University: https://dc.etsu.edu/etsu-works/9437

applied
sciences
Review

Microgravity, Bone Homeostasis, and Insulin-Like
Growth Factor-1
John Kelly Smith
Departments of Academic Affairs and Biomedical Sciences, James H. Quillen College of Medicine,
East Tennessee State University, P.O. Box 70300, Johnson City, TN 37614, USA; smithj@etsu.edu;
Tel.: +1-423-794-7425
Received: 17 May 2020; Accepted: 24 June 2020; Published: 27 June 2020




Abstract: Astronauts at are risk of losing 1.0–1.5% of their bone mass for every month they spend in
space despite their adherence to high impact exercise training programs and diets high in nutrients,
potassium, calcium, and vitamin D, all designed to preserve the skeletal system. This article reviews
the basics of bone formation and resorption and details how exposure to microgravity or simulated
microgravity affects the structure and function of osteoblasts, osteocytes, osteoclasts, and their
mesenchymal and hematologic stem cell precursors. It details the critical roles that insulin-like
growth factor-1 and its receptor insulin-like growth factor-1 receptor (GFR1) play in maintaining
bone homeostasis and how exposure of bone cells to microgravity affects the function of these growth
factors. Lastly, it discusses the potential of tumor necrosis factor-related apoptosis-inducing ligand,
syncytin-A, sclerostin inhibitors and recombinant IGF-1 as a bone-saving treatment for astronauts in
space and during their colonization of the Moon.
Keywords: Insulin-like growth factor-1; insulin-like growth factor-1 receptor; microgravity;
osteoblasts; osteocytes; osteoclasts; IGF-1; IGF1R; rIGF-1; TRAIL; syncytin-A; sclerostin;
bisphosphonates; romosozumab

1. Introduction
All terrestrial forms of life have had millions of years to adapt to Earth’s gravity (9.8 m/sec2 ).
Cytoskeletons constructed with actin, microfilaments and microtubules resist compressive forces and
allow internal load bearing [1]. Adhesive molecules such as integrins deal with external compressive
forces and allow cells to maintain their positions in space [2]. Mechanosensors shuttling between
cytoplasmic membranes and nuclei and matrix clusters of cell extension kinases keep the cell informed
of needed changes in gene expression [3,4]. Gravisensing organelles inform roots and stems which
direction in space they should occupy [5]. And cells use thermal convection in which heated fluids
rise to the top of the gravity vector and are then exchanged by cooler fluids, establishing a convection
current that dissipates heat, renews nutrient supplies, and removes waste materials [6].
Nature is the ultimate architect and has done well by its creatures on Earth. But man has thrown
nature a curve ball and ventured into space where all these adaptations are obsolete.
The adverse effects of microgravity are particularly severe on the musculoskeletal system,
particularly bone. Astronauts at are risk of losing 1.0–1.5% of their bone mass for every month they
spend in space despite their adherence to high impact exercise training programs, and diets high in
nutrients, potassium, calcium, and vitamin D, all designed to preserve the skeletal system. And the
adverse effects of space travel on the skeletal system may persist for years after returning to Earth.
In this review, I detail the effects of microgravity on bone homeostasis and review the prominent
roles that insulin-like growth factor-1 and its receptor, IGF-1R, play in the growth and maintenance
this vital tissue.
Appl. Sci. 2020, 10, 4433; doi:10.3390/app10134433
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3.1. Osteocytes
Exposure of osteocytes to shear stress generated in blood vessels within the Volkmann and
Exposure of osteocytes to shear stress generated in blood vessels within the Volkmann and
Haversian canals and interstitial fluid in the lacunar-canalicular network and in spaces between the
Haversian canals and interstitial fluid in the lacunar-canalicular network and in spaces between the
crystallites of the mineral hydroxyapatite and collagen fibers distorts their shape and activates the
crystallites of the mineral hydroxyapatite and collagen fibers distorts their shape and activates the
Wnt signaling pathway via translocation of β-catenin to the nucleus [8]. Wnt signaling is critical
Wnt signaling pathway via translocation of β-catenin to the nucleus [8]. Wnt signaling is critical for
for bone mass accrual, bone remodeling, and fracture repair, and loss of function in Wnt or in
bone mass accrual, bone remodeling, and fracture repair, and loss of function in Wnt or in mutations
mutations of its co-receptor LRP5 result in low bone mass and an increase in fragility fractures [8–10].
of its co-receptor LRP5 result in low bone mass and an increase in fragility fractures [8–10]. Cell shape
Cell shape distortion involves cytoskeletal rearrangement of actin fibers and microtubules, both of
distortion involves cytoskeletal rearrangement of actin fibers and microtubules, both of which are
which are known to be integral players in mechanotransduction. Osteocyte cilia, dendritic extensions,
known to be integral players in mechanotransduction. Osteocyte cilia, dendritic extensions, and
and integrins in the extracellular matrix also act as mechanosensors [10,11]. Hillsley and Frangos
integrins in the extracellular matrix also act as mechanosensors [10,11]. Hillsley and Frangos propose
propose that the bone loss observed in disuse and microgravity is due to a lack or decreased interstitial
that the bone loss observed in disuse and microgravity is due to a lack or decreased interstitial fluid
fluid flow [12].
flow [12].
Liu and associates have shown that osteocytes also respond to changes in hydraulic pressure.
Liu and associates have shown that osteocytes also respond to changes in hydraulic pressure.
Cultures of osteocyte-like MLO-Y4 cells sensed cyclic changes in hydraulic pressure and responded by
Cultures of osteocyte-like MLO-Y4 cells sensed cyclic changes in hydraulic pressure and responded
increasing intracellular calcium concentrations, COX-2 levels, and RANKL/osteoprotegerin mRNA
by increasing intracellular calcium concentrations, COX-2 levels, and RANKL/osteoprotegerin
ratios, and by altering cytoskeleton organization of actin and microtubules [13]. Mobilization of
mRNA ratios, and by altering cytoskeleton organization of actin and microtubules [13]. Mobilization
intracellular calcium activates downstream signaling of protein kinase A (PKA), MAPK, c-Fos,
of intracellular calcium activates downstream signaling of protein kinase A (PKA), MAPK, c-Fos, and
and prompts nuclear translocation of NF-κB. Blocking calcium release attenuates the mechanically
prompts nuclear translocation of NF-κB. Blocking calcium release attenuates the mechanically
induced upregulation of osteogenic gene expression in vitro and abrogates load-induced bone formation
induced upregulation of osteogenic gene expression in vitro and abrogates load-induced bone
in vivo. COX-2 is the gene that encodes cyclooxygenase-2, a mediator of prostaglandins that play a
formation in vivo. COX-2 is the gene that encodes cyclooxygenase-2, a mediator of prostaglandins
role in bone homeostasis [13,14].
that play a role in bone homeostasis [13,14].
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3.2. Osteoblasts
Young and associates found that reduced levels of osteoblast mechanostressors activates
mechanotransduction via focal adhesion kinase (FAK) contained within extracellular matrix signaling
complexes. Osteoblasts respond by increasing the expression of proteins involved in bone formation,
such as COX-2, c-Fos and osteopontin E2 [15]. Ban and associates found that osteoblasts subjected to
low levels of fluid shear stress proliferated and increased their production of bone markers including
alkaline phosphatase and osteocalcin [16].
3.3. Osteoclasts
Osteoclast responses to mechanical loading are mediated by osteoblasts and osteocytes.
Mechanically stimulated osteoblasts inhibit osteoclastogenesis by producing protegerin; this decoy
receptor binds RANKL and prevents it from binding to receptors on osteoclast hematologic stem cells.
Osteocytes control osteoclast activity by secreting sclerostin, a mechanosensing protein that increases
bone resorption while decreasing bone formation [17].
Other structures within bone may also play a role in the response of bone to mechanical forces,
including ion channels, connexins, integrins, and the glycocalyx [8,11].
4. Mechanotransduction in Space (1 × 10−6 g)
4.1. Osteocytes
Osteocytes are particularly susceptible to the adverse effects of zero gravity. In mice, one month
of spaceflight decreased femoral trabecular bone volume by 64% and increased bone resorption by
140% when compared to ground controls. These changes were associated with osteocyte apoptosis,
reductions in osteocyte lacunar volumes, and increases in lacunar vacancies (+344% vs. ground controls);
fatty metamorphosis of mesenchymal stem cell precursors was also observed [18]. Similar findings
were noted in iliac crest biopsies of monkeys flown for 14 days at zero gravity [19].
4.2. Osteoblasts
A site-specific bone loss of 1–2% occurs in astronauts and in-flight animals after 1 month of
spaceflight. The loss is associated with changes in osteoblast cellular and nuclear morphology and
altered mRNA expression of type I collagen, osteocalcin, and insulin-like growth binding proteins [20].
Nabavi and associates found that osteoblasts subjected to 5 days of microgravity had extended shapes,
fragmented or condensed nuclei, shorter microtubules, and smaller and fewer focal adhesions [21].
Hughs-Fulford found that serum-activated osteoblasts had a 60% reduction in growth as compared
to ground controls, presumably due to alterations in growth factor receptors and/or cell-connected
matrix kinase pathways. After 4 days in space there was a loss of focal adhesions and a complete
collapse of the osteoblast cytoskeleton. He postulated that the collapse was due to F-actin microfilament
failure and/or inhibition of microtubular polymerization [22]. The same investigator had previously
reported that cultured osteoblasts had increased levels of C-fos mRNA and diminished levels of Cox-2
mRNA [23]. C-fos is a protooncogene that encodes a 62 kDa protein that forms a heterodimer with c-jun
(part of the jun family of transcription factors) resulting in the formation of activator protein 1 (AP-1)
complex which binds DNA at AP-1 specific sites at the promoter and enhancer regions of target genes
and converts extracellular signals into signals of gene expression. Cox-2 catalyzes the rate-limiting
step in prostaglandin synthesis. Using cultures of ROS 17/2.8 osteoblasts, Guignandon and associates
reported that osteoblastic integrin-mediated cell adhesion was disrupted in cells flown for six days on
the space shuttle. The changes were characterized by disorganization of the cytoskeleton associated
with disassembling of vinculin spots and phosphorylated proteins within the focal contacts [24]
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4.3. Osteoclasts
Differentiated osteoclasts cultured on bone substrates for 10 days of zero gravity increased their
expression of genes involved in osteoclast maturation and bone resorption when compared to ground
controls [25].
5. Mechanotransduction in Simulated Microgravity (g ≥ 10−3 )
5.1. Osteocytes
Robling and associates investigated the mechanoregulation of sclerostin and its regulatory gene
Sost in rodent osteocytes under enhanced (ulnar loading) and reduced (hindlimb unloading) conditions.
Sost transcripts and sclerostin protein levels were reduced in loaded bone and increased in unloaded
bone [17]. Lin and associates found that mechanical unloading of wildtype mice caused a decrease in
Wnt/beta-catenin signaling accompanied by increases in Sost and sclerostin production and reductions
in bone formation and in the viability of osteocytes and osteoblasts [26].
5.2. Osteoblasts
Using NASA’s rotary cell culture system, Saxena and associates found that modeled
microgravity inhibited osteoblastogenesis and increased adipose differentiation in human stem cells.
The transformation involved reductions in RhoA activity and cofilin phosphorylation, disruption of
F-actin stress fibers, and decreased integrin signaling through focal adhesion kinase [27]. Employing the
same culture system, Ontiveros and McCabe reported a 50–80% reduction in alkaline phosphatase,
Runx2, osteocalcin expression, and AP-1 transactivation in cultures of rat osteoblasts [28], and Patel
and associates noted that 3 days of rotation altered the expression of 61 mechanosensitive genes,
including osteomodulin, Runx2, and osteoglycin in cultures of mouse tibial pre-osteoblasts [29].
Using two-axis random positioning machines, Shi and associates found that simulated microgravity
inhibited rat calvarial osteoblast differentiation, maturation, and ciliogenesis and attributed the
change to atrophy of osteoblast cilia [30]. Sun and associates found that simulated microgravity
reduced intracellular free calcium levels by inhibiting calcium channels in mouse osteoblasts [31].
As previously noted, low levels of intracellular calcium impairs osteogenic gene expression in vitro
and abrogates load-induced bone formation in vivo. Dai and associates found that simulated
microgravity inhibited the proliferation and osteogenesis of rat bone marrow mesenchymal stem
cells [32]. Using cultures of human bone marrow mesenchymal stem cells, Li and associates found that
simulated microgravity inhibited genes regulating proliferation and differentiation while upregulating
genes involved in adipogenesis [33]. Chen and associates found that simulated microgravity inhibited
osteogenic differentiation of mesenchymal stem cells by inhibiting the expression of transcriptional
coactivator with PDZ-binding motif, an important regulator of osteogenesis [34]
Experiments measuring the metabolomics and proteomics of cultured human osteoblasts found
that simulated microgravity caused a decrease in mitochondrial proteins, a reduction in mitochondrial
energy potential, and an oxidative stress response (decreases in oxidized glutathione and antioxidant
enzymes) [35].
5.3. Osteoclasts
Using NASA’s rotary cell culture system and mouse bone marrow cultures, Sambandam and
associates found that simulated microgravity enhanced the maturation of osteoclast precursors [36,37].
Ethiraj and associates reported similar findings noting that osteoclastogenesis was associated with
increased stem cell expression of syncytin-A [38]. Rucci and associates found that modeled microgravity
stimulated osteoclastogenesis and bone resorption by increasing osteoblast RANKL/osteoprotegerin
ratios [39], and Saxena and associates found that modeled microgravity and hindlimb unloading
sensitized osteoclast precursors to RANKL-mediated osteoclastogenesis [40] (see Table 1).
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Table 1. Effects of gravity on osteocyte, osteoblast, osteoclast and mesenchymal and hematopoietic stem cell precursors.
Mechanostressors

Gx1
Increased Wnt/beta-catenin,
calcium, COX-2 signaling,
RANKL/OPG mRNA ratios.
Cytoskeletal reorganization [8–14]

G ≥ 10−3

G = 10−6

Increased Sost expression, sclerostin
production. Decreased Wnt/beta-catenin
signaling, bone formation [17,26]

Apoptosis
Sclerostin release [18,19]

Osteocytes *

Fluid shear stress
Hydrostatic pressure [8–14]

Osteoblasts

Bone loading via
FAK
Fluid shear stress [15,16].

Increased bone formation via
enhanced expression of COX-2,
c-Fos, osteopontin E2 [15,16]

Decreased expression of mechanosensitive
genes & markers of bone formation.
Calcium channel inhibition [27–34]

Loss of focal adhesions, FAK.
F-actin micro-filament &
microtubular failure with
cytoskeleton implosion [20–24]

Osteoclasts

As per osteocytes & osteoblasts

Resorption inhibited by osteoblast
production of OPG and by reduced
production of sclerostin by
osteocytes [17,26]

Increased osteoclastogenesis and bone
resorption secondary to increased
RANKL/OPG ratios [36–40]

Increased expression of genes
involved in osteoclast
maturation and bone
resorption [25]

Mesenchymal stem cells

Decreased osteoblast differentiation,
maturation & ciliogenesis.
Increased adipogenesis [27,32–34]

Hematopoietic stem cells

Enhanced maturation.
Increased expression of syncytin-A.
Increased response to RANKL-mediated
osteoclasto-genesis [36–40]

* Mechanosensors include the cytoskeleton, actin microfibers, microtubules, cilia, dendritic extensions and integrins in the extracellular matrix. COX-2, cyclooxygenase-2;
FAK, focal adhesion kinases; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor kappa B ligand; Sost, gene encoding sclerostin.
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6. The Somatotrophic Axis
The somatotropic axis consists of hormonal circuits that regulate somatic growth, including body
and bone mass, body adiposity, and lipid and carbohydrate metabolism. The axis includes growth
hormone-releasing hormone (GHRH), growth hormone (GH), insulin-like growth factors (IGFs) 1 & 2
and their receptor, IGF1R, six IGF binding proteins (IGFBPs), the acid-labile subunit (ALS), somatostatin,
and ghrelin (see Figure 3). Also included are growth hormone receptor’s downstream mediators,
Janus kinase 2 (JAK2), signal transducer and activator of transcription 5 (STAT5) and suppressors of
cytokine signaling 1–3 (SOCS1-3) [7]. IGF-2 is primarily involved in the growth and development of
Appl. Sci. 2020, 10, and
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like growth factor-1 and some of its binding proteins. Circulating IGF-1 reaches the bone matrix where
it and some of its binding proteins are produced primarily by osteoblasts in an autocrine/paracrine
it and some of its binding proteins are produced primarily by osteoblasts in an autocrine/paracrine
manner. Released from its binding proteins by proteases, IGF-1 binds to its receptor IGF1R initiating
manner.
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6.1. Insulin-Like Growth Factor-1 (IGF-1)
8. IGF-1 and Mechanical Loading
IGF-1 is structurally related to insulin. It consists of 70 amino acids in a single chain with three
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free, biologically active state, which has a half-life of ~10 min. IGFBP binding prolongs the half-life of
IGF-1 and assists in its delivery to specific tissues [7].
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that microgravity completely suppressed mRNA expression of the insulin receptor substrate-1, a
post-receptor signaling molecule of IGF-1 [53]. Sakata and associates found that skeletal unloading
induces resistance to IGF-1 by inhibiting the activation of IGF-signaling pathways including the
expression of alphaVbeta3 integrin [54]. And Triplett et al. found that mechanical loading by fluid
shear stress enhanced IGF-1R signaling in osteoblasts whereas mechanical unloading inhibited its
signaling [51]. Kostenuik and associates found that skeletal unloading caused resistance of
osteoprogenitor cells to parathyroid hormone due to the development of resistance to IGF-1 [48].
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6.2. Insulin-Like Growth Factor-1 Receptor (IGF-1R)
Although IGF-1 can bind to insulin receptors, its primary action is mediated when it binds to
its main receptor, IGF-1R. IGF-1R is a class II receptor tyrosine kinase (RTK) which plays a critical
role in cell growth and differentiation. Binding of one IGF-1 molecule is sufficient to break the
autoinhibited state of IGF-1R and initiate receptor activation. This results in the activation of a
variety of intracellular transduction cascades including phosphatidlyinositol-3 kinase (PI3K) and its
downstream target, mammalian target of rapamycin (mTOR) [41,42]. Recently, IGF-IR has been shown
to have extensive cross-talk with many other receptors and can function as an RTK/GPCR hybrid.
In addition, after activation, IGF-IR may translocate to the nucleus and function as a transcriptional
cofactor; alternatively, it is recycled to the surface or degraded [43].
7. IGF-1 and Bone Homeostasis
IGF-1 is the most abundant growth factor in bone matrix [42] where it is synthesized by osteoblast
mesenchymal precursors, mature osteoblasts, osteoclasts and osteocytes [44,45]. Osteoblasts also
produce all the IGFBPs [45]. Hepatocyte synthesized IGF-1 is distributed to the matrix via the bone’s
nutrient and periosteal arteries located within the Volkmann and Haversian canals.
In bone, IGF-1 regulates periosteal bone expansion (radial bone growth) by its effects on
osteoprogenitors at the periosteal or endocortical bone surfaces. Linear bone growth is controlled by
growth hormone which stimulates chondrocyte precursors to produce IGF-1 which then acts in an
autocrine fashion to induce the production of type II collagen1a via activation of the phosphatidylinositol
3-kinase/phosphoinositide-dependent kinase-1 pathway. With progression of chondrocytes to terminal
differentiation, IGF1R signaling is terminated [46]. IGF-1 regulates bone mass by activation of mTOR
in mesenchymal stem cell progenitors of osteoblasts [47].
IGF-1 has pro-differentiating and pro-survival effects on osteoblasts and their mesenchymal
precursors and is essential for the anabolic actions of parathyroid hormone (PTH) on bone [48].
Activation osteoblast IGF1R initiates the expression of the runt-related transcription factor 2 (Runx2)
which stimulates the transition of mesenchymal stem cells into osteoprogenitors. Downstream of
Runx2 is osterix (osx) which controls the maturation of osteoprogenitors into mature osteoblasts.
Osteoblasts are responsible for the production and secretion of the extracellular matrix and expresses
genes involved in matrix calcification [45].
Osteoclasts differentiate from mononuclear progenitors in the presence of macrophage colony
stimulating factor (M-CSF) and RANKL. Wang and associates found that mRNA expression of RANKL,
RANK, and M-CSF was diminished by 35–60% in IGF-1 knockout mice and led to a reduction
in osteoclastogenesis [49]; the results confirm the importance of IGF-1 in promoting osteoclast
differentiation from hematologic stem cell precursors.
Both animal and human studies have shown that circulating levels and locally produced
autocrine/paracrine sources of IGF-1 each play an important role in achieving peak bone mass
and strength [7,44].
8. IGF-1 and Mechanical Loading
In vitro experiments of cultured MC3T3-E1 osteoblast-line cells have shown that mechanical
loading generated by interstitial fluid shear stress protects osteoblasts from tumor necrosis factor-α
-mediated apoptosis [50] and that the protection is mediated by flow-enhanced IGF-1-rceptor
signaling [51]. Osteoblast deletion of IGF-1 or IGF1R abates the osteogenic response to mechanical
loading whereas transgenic overexpression of IGF-1 in osteoblasts results in an enhanced responsiveness
to in vivo mechanical loading in mice [52].
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9. IGF-1 and Mechanical Unloading
Studies during spaceflight and in bone unloading experiments on Earth have shown that bone
unloading suppresses IGF-1 production (see Figure 4). Kumei et al. found that spaceflight decreased
mRNA levels of IGF-1 in cultures of rat osteoblasts as compared to ground controls; they also
found that microgravity completely suppressed mRNA expression of the insulin receptor substrate-1,
a post-receptor signaling molecule of IGF-1 [53]. Sakata and associates found that skeletal unloading
induces resistance to IGF-1 by inhibiting the activation of IGF-signaling pathways including the
expression of alphaVbeta3 integrin [54]. And Triplett et al. found that mechanical loading by
fluid shear stress enhanced IGF-1R signaling in osteoblasts whereas mechanical unloading inhibited
its signaling [51]. Kostenuik and associates found that skeletal unloading caused resistance of
toREVIEW
parathyroid hormone due to the development of resistance to IGF-1 [48].
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production, signaling, and IGF-1-mediated bone formation by osteoblasts and enhances IGF-1
resistance in osteoblast mesenchymal stem cell precursors. In contrast, bone loading increases IGF-1
PTH resistance in osteoblast mesenchymal stem cell precursors. In contrast, bone loading increases
production and IGF1R efficiency and decreases TNF-α-mediated apoptosis in osteoblasts. Deletion of
IGF-1 production and IGF1R efficiency and decreases TNF-α-mediated apoptosis in osteoblasts.
IGF-1 or IGF1R in rodents abrogates osteoblast responses to bone loading and unloading (not shown).
Deletion of IGF-1 or IGF1R in rodents abrogates osteoblast responses to bone loading and unloading
(not Hind
shown).
limb suspension in rats has been shown to inhibit IGF1R signaling pathways with consequent
reduction in the number and differentiation of osteoblast progenitors and reduced bone formation;
10. Discussion
responsiveness to IGF1R could be restored with reloading [54,55]. In contrast, unloading of IGF-1R
knockout mice caused a permanent loss of bone synthesis, indicating that IGF1 signaling is necessary
Many of the studies on bone homeostasis in space and in terrestrial models of microgravity are
for bone formation following disuse or zero gravity [7,44].

motivated by the need to find treatments capable of abrogating the bone loss that occurs despite
NASA’s implementation of exercise and dietary regimens designed to maintain bone homeostasis.
Although most recommendations are non-specific, a few have suggested specific targets to
investigate. These include TRAIL [37], syncytin-A [38], sclerostin [26], and rIGF-1 [54–56]. I provide
below a table (Table 2) outlining NASA’s current approach to maintain bone health during
spaceflight [57–61] as well as a brief discussion of the aforementioned targets in ascending order of
potential.
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10. Discussion
Many of the studies on bone homeostasis in space and in terrestrial models of microgravity are
motivated by the need to find treatments capable of abrogating the bone loss that occurs despite
NASA’s implementation of exercise and dietary regimens designed to maintain bone homeostasis.
Although most recommendations are non-specific, a few have suggested specific targets to investigate.
These include TRAIL [37], syncytin-A [38], sclerostin [26], and rIGF-1 [54–56]. I provide below a
table (Table 2) outlining NASA’s current approach to maintain bone health during spaceflight [57–61]
as well as a brief discussion of the aforementioned targets in ascending order of potential.
Table 2. Measures currently taken to help prevent bone loss during spaceflight [57–61].
Exercise

2.5 h/day x 6 days a week
of combined aerobic &
resistance exercises

Nutritious High Calory Diet
Calories: 2700 to 3700/day *
Frozen foods: Most entrees,
vegetable and fruit items.
Refrigerated foods: Fresh and
fresh treated fruits, vegetables
and dairy products.
Ambient foods:
Thermostabilized, aseptic-fill,
shelf-stable natural form foods
and rehydrated beverages

Vitamins/Minerals

Bone Sparing Agents

Recommended daily
allowance (RDA) of
vitamins & minerals.
1000–1200 mg calcium &
800 IU vitamin D/day
(Smith et al.)

† Biphosphonates

* Calorie requirements are determined by the National Research Council formula for basal energy expenditure
(BEE). For women, BEE = 655 + (9.6 × W) + (1.7 × H) – (4.7 × A); for men BEE = 66 + (13.7 × W) + (5 × H)−(6.8 × A),
where W = weight in kg, H = height in cm, and A = age in years. Astronauts choose their menu approximately
28 days preflight. † Joint studies between NASA and JAXA suggest that alendronate may be helpful in preventing
bone loss during spaceflight but concerns about side effects remain. Despite the implementation of this exercise and
dietary regimen, astronauts lose 1–1.5% of their bone mass for every month they spend in space.

10.1. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)
TRAIL is a cytokine of the TNF superfamily known for its ability to trigger apoptosis in tumor
cells while being relatively safe towards normal cells. Binding to its cognate receptors, TRAIL-R1 or
TRAIL-R2, induces the formation of a macromolecular complex that recruits caspase-8 and caspase-10
to initiate apoptosis [62,63]. Although TRAIL has been shown to trigger osteoclast apoptosis, in the
opinion of the author it is unlikely that this cytokine could be ever be used to target only osteoclasts
and titer its use in such a way that the subject does not develop osteopetrosis.
10.2. Syncytin-A
Syncytin-A is an intact retroviral envelope protein, the product of a retrovirus gene that was inserted
into the human genome somewhere between 10 and 80 million years ago [64]. Syncytin-A is called a
syncytin because of its membrane fusogenic capacity. In bone, syncytin A fuses the membranes of
mononucleated pre-osteoclasts producing mature multinucleated osteoclasts. However, pre-osteoclast
fusion is also mediated by CD47 and syncytin-A plays a critical role in the fusion of the placental
syncytiotrophoblast [64–66]. In the opinion of the author, this makes syncytin an unlikely candidate
to target with monoclonal antibody. More suited for this purpose and currently under widespread
use are the biphosphonates, whose effects include osteoclast apoptosis. Potential complications of
oral bisphosphonate therapy include esophagitis and, rarely, osteonecrosis of the jaw. When given
intravenously, biphosphonates can cause a flu-like illness with fever, myalgias, and arthralgias [60].
10.3. Sclerostin
Sclerostin, a 22-kD glycoprotein secreted primarily by osteocytes, is a soluble inhibitor of canonical
Wnt/β-catenin signaling pathways that direct mesenchymal stem cells towards the osteoblastic lineage.
Sclerostin also enhances bone resorption by decreasing the production of osteoprotegerin, the soluble
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decoy receptor that inhibits osteoclastogenesis by binding RANKL. Thus, when present in high
concentrations sclerostin causes decreased bone formation and increased bone resorption [67].
Scientists have recently developed a humanized monoclonal antibody directed against sclerostin
(romosozumab) which was approved by the FDA for treatment of osteoporosis in 2019. Clinical trials
have shown that monthly subcutaneous injections of romosozumab is effective in increasing bone
formation and density and in decreasing bone resorption, results in keeping with the known effects of
sclerostin on bone homeostasis [68]. However, there is some concern about potential cardiotoxicity of
romosozumab, prompting the need for further clinical observations [69].
10.4. IGF-1
The potential role of rIGF-1 in maintaining skeletal mass in space was recognized by Tanaka and
associates who found that the complex IGF-1 and its specific binding protein, IGFBP-3 stimulated bone
turnover in an animal model flown in space [55]. Bateman and associates found that administration of
IGF-1 to rodents flown for 10 days aboard the Space Shuttle increased their humerus periosteal bone
formation by 37.6% [56].
In light of the central role that IGF-1 plays in all phases of bone formation and preservation, it is
perhaps surprising that there are no published proof of principle trials assessing the efficacy of rIGF-1
in preventing bone loss in astronauts, particularly in light of the fact that rIGF-1 is available in an easy
to use nasal spray and when used judiciously is generally well tolerated [70]. IGF-1 administration
would have the added advantage of bolstering muscle growth and exerting a positive effect on
immunoregulation. rIGF-1 has been used to treat patients with IGF-1 deficiency, adolescents with
anorexia nervosa and low bone mass, and patients with diabetes mellitus, a disorder characterized by
low circulating levels of IGF-1. The side effects of rIGF-1 are dose-related and may include extremity
edema, jaw pain, arthralgias, myalgias, and hypoglycemia [71,72].
It is recognized that IGF1/IGF1Rt studies done under simulated conditions of microgravity do
not necessarily equate with those done in the zero gravity of space. Simulated microgravity studies
achieve at best a thousand-fold reduction in gravitational forces (≥1 × 10−3 g) whereas in space
the force of gravity is a million-fold less than that experienced on Earth (1 × 10−6 g). As noted
in this review, osteoblasts grown in space have extended cell shapes, fragmented and condensed
nuclei, shortened microtubules, defective actin microfilaments, smaller and fewer focal adhesions,
and even a complete implosion of the cytoskeleton. In contrast, osteoblasts grown in simulated
microgravity are characterized more by disruption in functional than in structural aberrations. Thus,
although rIGF-1 proved useful in reversing the recalcitrance of blastocytes to mechanostressors in
simulated microgravity, the same may not be true in space.
Unfortunately, the adverse effects of microgravity on the skeletal system may persist for years
postflight. In addition, astronauts experience a variety of other stressors, including social isolation,
sleep deprivation, confinement, solar radiation, and alterations in circadian rhythms; on landing they
experience the stress of the sudden readjustment to Earth’s gravity field [73].
In their approach to future space missions, scientists are faced with the need to carefully balance
factors that enhance bone loss with those that have the potential to prevent or remit bone loss (see Figure 5).
The United States, Russia, and China are planning to establish colonies on our moon sometime in
the 2030s. The force of gravity on the Moon is 1.6 m/s2 which is 16.7% of Earth’s gravity or ~1 × 10−2 g,
well within the range of simulated microgravity studies already performed. It would seem that rIFG-1
may hold greater promise as a therapy to abrogate hypogravity-related changes in bone homeostasis
in astronauts destined to colonize the moon than those aboard a spaceship.
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sleep deprivation, confinement, solar radiation, and alterations in circadian rhythms; on landing they
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homeostasis in astronauts destined to colonize the moon than those aboard a spaceship.
2.
Zero and modeled microgravity adversely affect all four phases of bone formation, increasing the
maturation and the resorptive activities of osteoclasts, decreasing the differentiation, maturation,
and bone forming abilities of osteoblasts, and causing apoptotic-mediated death of osteocytes
with consequent dysregulation of bone homeostasis.
3.
Microgravity-associated changes in osteoblast microstructure include extended cell shapes,
fragmented and condensed nuclei, shortened microtubules, smaller and fewer focal adhesions,
and even complete collapse of the cytoskeleton due to microfilament and/or microtubular failure.
Osteocyte death is reflected by increases in lacunar vacancies and volumes and in the production of
sclerostin, a mechanosensitive protein that inhibits bone formation and enhances bone resorption.
4.
IGF-1 and its receptor IGF1R play critical roles in all phases of bone formation, promoting
both radial and linear bone growth. Osteocyte and osteoblast responses to mechanostressors is
IGF-1/IGF1R dependent and deletion of IGF-1 or IGF1R genes abates their responses to mechanical
unloading and reloading. Treatment with recombinant IGF-1 (rIGF1) reverses these defects
when IGF1R is intact, raising the prospect that rIGF-1 may prove useful in preventing bone loss
associated with space travel or, more likely, in the microgravity of the Moon. Another potential
candidate to prevent bone loss in space or on the Moon is romosozumab, a humanized antibody
against sclerostin which has been approved by the FDA for treatment of osteoporosis.
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